Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study

Current Medical Research and Opinion

Volumn 27, Issue 2, 2011, Pages 365-374

  King, D ^a   Knapp, M ^a   Thomas, P ^b   Razzouk, D ^c   Loze, J Y ^d   Kan, H J ^e   Van Baardewijk, M ^e  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Otsuka Pharmaceuticals France   (France)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Cost effectiveness; Schizophrenia; STAR study

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL CARE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLONES; RESIDENCE CHARACTERISTICS; SCHIZOPHRENIA; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 78651396683     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.542745     Document Type: Article

References (37)

1. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) Study. Eur Psychiatry 2007;22:433-43
2. Andlin-Sobocki P, Rossler W. Cost of psychotic disorders in Europe. Eur J Neurol 2005;12:74-7
3. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007;10:23-41
4. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
5. Briggs A, Wild D, Lees M. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
6. Kolotkin RL. Mean change in the Impact of Weight on Quality of Life (IWQOL-Lite) score at Week 26 during the Schizophrenia Trial of Aripiprazole (STAR) study. Poster presented at the American Psychiatric Association annual meeting, 20-25 May 2006, Toronto, Canada
7. APA. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision). American Psychiatric Publishing, Inc., 2000
8. Tandon R, Devellis RF, Han J, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005;136:211-21
9. Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98
10. Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102-11
11. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87
12. Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004;57:1153-60
13. Chisholm D, Knapp MR, Knudsen HC, et al. Client Socio-Demographic and Service Receipt Inventory - European version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Br J Psychiatry 2000;177(Suppl.):s28-s33
14. CIPFA. Education Statistics 1999-2000. Actuals. London: Chartered Institute of Public Finance and Accountancy, 2000
15. Harries R. The Cost of Criminal Justice: Home Office Research Findings. No. 103. London: Home Office, 1999
16. Finn W, Hyslop J, Truman C. Mental Health, Multiple Needs and the Police. London: Revolving Doors Agency, 2000
17. Netten A, Curtis L. Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, 2002
18. NHS, NHS Trusts Department of Health. National schedule of reference costs. Available at: http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/dh/en/documents/digitalasset/dh-4070110.xls [Last accessed April 2010]
19. Netten A, Curtis L. Unit Costs of Health and Social Care. Canterbury: University of Kent, 2003
20. Curtis LA. Unit Costs of Health and Social Care. Canterbury: University of Kent, 2009
21. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005;14:763-76
22. Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis, Chapter 17. London: Chapman &Hall, 1995
23. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987
24. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3:309-19
25. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15
26. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219-36
27. Dunn G, Mirandola M, Amaddeo F, et al. Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br J Psychiatry 2003;183:398-404
28. STATA. Stata Corp. Strata statistical software: release 10. College Station, TX: StataCorp LP, 2007
29. Drummond MF, Pang F. Transferability of economic evaluation results. In: Drummond MF, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001
30. Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsy-chotics and risk of diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008;192:406-11
31. Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry 2008;69:741-8
32. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical anti-psychotic drugs in schizophrenia. Health Technol Assess 2003;7:1-193
33. Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res 2004;71:445-62
34. Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 2008;26:341-58
35. Davies LM, Barnes TR, Jones PB, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health 2008;11:549-62
36. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-9
37. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-36